

<b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. <b>MGH-028AUS</b>	APPLICATION NO. <b>10/814,852</b>
	APPLICANT <b>Maurizio Fava, et al.</b>	
	FILING DATE <b>March 31, 2004</b>	GROUP <b>3626</b>

Page 1 of 1

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE*

RECEIVED  
SEP 29 2009  
OFFICE OF PETITIONS

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	Brown, Jr.; "The Crossover Experiment for Clinical Trials;" Publication of Stanford University Medical Center, Stanford, CA; Biometrics 36; March 1980; pages 69-79
	Carriere; "Crossover Designs for Clinical Trials;" Statistics in Medicine; Vol. 13; April 1993; pages 1063-1069
	Farlow et al.; "A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer's Disease;" European Neurology; Vol. 4, November 2000; pages 236-241
	Hills et al.; "The Two-Period Cross-Over Clinical Trial;" British Journal of Clinical Pharmacology; July 1979; pages 7-20
	Leber et al.; "Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection;" Elsevier Science Inc.; Controlled Clinical Trials; Vol. 19, Issue 2 April 1998; pages 178-187
	Raskind et al.; "Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension;" American Academy of Neurology; June 2000; pages 2260-2269
	Rosner et al.; "Randomized Discontinuation Design: Applied to Cytostatic Antineoplastic Agents;" Journal of Clinical Oncology; Vol. 20, No. 22; November 15, 2002; pages 4478-4484
	Temple; "Special Study Designs: Early Escape, Enrichment, Studies in Non-Responders;" Communications in Statistics-Theory and Method; Vol. 23, Issue 2; 1994; pages 499-531
Examiner	<div style="text-align: center;">Date Considered:</div> <div style="font-size: 0.8em;">*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.</div>